Oral nicotinamide ribose (NR) in allogeneic hematopoietic stem cell transplant donors to promote stem cell mobilization: a single center, single arm clinical research

Oral nicotinamide ribose (NR) in allogeneic hematopoietic stem cell transplant donors to promote stem cell mobilization

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300075668

Enrollment

Unknown

Registered

2023-09-12

Start date

2023-09-20

Completion date

Unknown

Last updated

2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mobilization of donor allogeneic hematopoietic stem cell

Interventions

NR group:Before hematopoietic stem cell collection, oral NR 500mg 2/ day for 2 months

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (a) Age = 18 years, male or female; (b) hematopoietic stem cells donors; (c) Qualified pre-transplant donor medical examination with no contraindications to transplantation. The physical examination items are routine examination items for transplant donors, including blood routine, liver and kidney function electrolytes, myocardial enzyme profile, coagulation time, five items of thyroid function, immunoglobulin, antinuclear antibody spectrum, rheumatic series, six items of hepatitis B, hepatitis B and hepatitis penta, pre-transfusion examination, TORCH virus IgM and IgG, EBV antibody, blood giant cells and Epstein-Barr virus nucleic acid, urine and urine routine, electrocardiogram, cardiac ultrasound, abdominal ultrasound, chest CT or chest radiograph, bone marrow aspiration and bone marrow biopsy, for donors aged >50 years, Tumor markers need to be refined; (d) Be willing and able to provide informed consent; (e) Willingness to comply with research protocols and research requirements.

Exclusion criteria

Exclusion criteria: (a) Pregnant and lactating women; (b) Severe cardiac, liver, kidney and cerebral insufficiency; (c) Intolerance of oral medications; (d) Have other malignancies and are undergoing treatment.

Design outcomes

Primary

Measure	Time frame
The CFU fomated after vitro culture of donor stem cells;	—

Secondary

Measure	Time frame
Recipients Incidence of graft poor function;Donor Mononuclear cell count and CD34+ count of peripheral blood stem cells;Recipients Hematopoietic reconstitution time;Recipients Graft versus host disease;Recipients 1-year overall survival;Recipients 1-year relapse free survival;Recipients NR side effects;	—

Countries

China

Contacts

Public ContactXi Zhang

The Second Affiliated Hospital of the Army Medical University

zhangxxi@sina.com+86 138 0831 0064

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026